Prudential Financial’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-2,208
Closed -$225K 2721
2023
Q2
$225K Buy
+2,208
New +$209K ﹤0.01% 2400
2021
Q4
Sell
-2,365
Closed -$238K 2712
2021
Q3
$238K Buy
2,365
+205
+9% +$24K ﹤0.01% 2415
2021
Q2
$306K Buy
+2,160
New +$244K ﹤0.01% 2300
2020
Q2
Sell
-14,488
Closed -$2.09M 2483
2020
Q1
$2.09M Buy
14,488
+12,587
+662% +$2.43M ﹤0.01% 1351
2019
Q4
$389K Buy
+1,901
New +$347K ﹤0.01% 2133
2019
Q3
Sell
-2,186
Closed -$206K 2495
2019
Q2
$206K Buy
+2,186
New +$189K ﹤0.01% 2331

Other funds holding RETA

Prudential Financial's RETA Position: Q3 2023 in Review

Prudential Financial sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 2,208 shares — an estimated $225K sold.

Prudential Financial first reported a position in RETA in Q2 2019 and held it in 6 quarters. The position peaked at $2.09M in Q1 2020. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

  • Prudential Financial reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
  • Prudential Financial sold 2,208 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $225K.
  • Prudential Financial first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2019 and held it in 6 quarters.
  • Prudential Financial's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.09M in Q1 2020.
  • 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Prudential Financial's 13F filing for Q3 2023, filed 13 Nov 2023.